Compare PFX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | NSPR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 72.1M |
| IPO Year | N/A | 2009 |
| Metric | PFX | NSPR |
|---|---|---|
| Price | $40.44 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 435.0 | ★ 152.4K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.30 | $1.02 |
| 52 Week High | $53.59 | $2.93 |
| Indicator | PFX | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 32.05 |
| Support Level | $38.73 | N/A |
| Resistance Level | $42.54 | $2.49 |
| Average True Range (ATR) | 0.63 | 0.10 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 50.47 | 35.42 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.